Navigation Links
Financing of biotech companies so far in 2005: A Midwest odyssey

For a biotech company, raising money is a saga that never ends.

Just as you complete a round, you have to do two things: execute on the timely achievement of key milestones you identified for your new investors and look at the structuring of your next financing and where and who the money will come from. Most angel investors aren't repeti......

Full article >>> bove, only two of the companies had a share price above $10 per share, which is one indicator of IPO strength. Aspreva Pharmaceuticals was the only company to have a significant amount of money raised (i.e. above $75 million). So what makes for a successful IPO? It is a combination of factors including:

Market timing
Company credentials
Management team and track record
Pri......

Full article >>> s from a VC panel at the InvestMidwest conference, which was held recently in Kansas City. His remarks were in response to another west coast VC's comment that most biotech companies on the west coast are in a unique situation in that they are getting multiple term sheets for the funding of their deals. This is allowing them to pick the best deal.

Churchwell commented that the situation i......

Full article >>> illion last year (or a decline of 19 percent).

A key indicator for the Midwest biotech sector was VC activity in biotech. The first quarter showed a total of $781 million versus almost $1.4 billion last year (or a decline of 43 percent). Ouch!



Though we don't yet have data to show how the Midwest fared in this area, I'm willing to bet that it ......

Full article >>> lines.

The ramifications of the Bone Care deal are both good and bad for the Midwest. On the downside, there are only 25 publicly traded biotech companies in the Midwest. Two have been picked off this year: Orphan Medical (by Jazz Pharmaceuticals) and now Bone Care (also don't forget Esperion and Cima Labs in 2003).

On the positive side, there are some new multi-millionaire inves......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 05/11/05


Related biology technology :

1. Financing life science: The ongoing saga
2. Seed-Stage Venture Financing
3. Quintessence Secures Financing
4. The state of global biotech: An Ernst & Young perspective
5. Olympics of biotechnology has international flavor
6. Getting noticed in Genetown: Wisconsin biotech on display
7. Madison biotech NimbleGen files for IPO; one of states best-funded firms
8. Wisconsin biotech firm receives $107K NIH grant
9. Manufacturing partnership will move into biotech and biomedical spaces
10. Wisconsin wont get Georgia biotech without a fight
11. The 10 biggest events shaping biotech in 2006
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... ... announced the three Winners and six Finalists of the 2017 Blavatnik Regional Awards ... the Blavatnik Family Foundation and administered by the New York Academy of Sciences ...
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
(Date:10/11/2017)... Bay, Florida (PRWEB) , ... October 11, 2017 ... ... and Drug Administration (FDA) has granted orphan drug designation to SBT-100, its novel ... (sdAb) for the treatment of osteosarcoma. SBT-100 is able to cross the cell ...
Breaking Biology Technology:
(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):